Submit Manuscript  

Article Details

Use of Oritavancin (Novel New Lipoglycopeptide) in the Treatment of Prosthetic Joint Infections (PJI): A Possible Alternative Novel Approach to a Difficult Problem

[ Vol. 17 , Issue. 2 ]


Suresh J. Antony* and Leigh G. Cooper   Pages 77 - 80 ( 4 )


Prosthetic joint infections (PJI) result in significant morbidity, mortality and cost to patients and the health system. Traditional treatment involves a twostaged revision and occasionally a single staged revision along with intravenous antibiotics (IV) and or oral antibiotics for several weeks to months. The use of a single staged revision along with an antibiotic which has a prolonged half life and is bactericidal would be ideal. We present 2 patients who were treated successfully with a single stage revision/antibiotic spacer and a new novel long acting lipoglycopeptide called oritavancin.


Oritavancin, prosthetic joint, intravenous, lipoglycopeptide, Morbidity, lipoglycopeptide.


1205 N. Oregon, El Paso, Texas 79902, Department of Medicine, Section of Infectious Diseases, Texas Tech University Health Sciences Center, El Paso, Texas

Graphical Abstract:

Read Full-Text article